Medivir AB (OMX: MVIR) announced it has initiated a phase I clinical trial with a cathepsin K inhibitor MIV-711 for the treatment of bone disorders such as osteoporosis, osteoarthritis and bone metastases. This is the first clinical study in humans with the compound. Biomarker information on both and cartilage turnover will be studied and based on the outcome a decision on possibly further development will be made.
The reversible inhibitor of cathepsin K will be offered to healthy volunteers as a single ascending oral dose repeated once a week while mainly assessing the safety, tolerability and pharmacokinetics. The study will include postmenopausal women who will be received the investigational drug once every two weeks. Results are expected in Q1 2013. The stock made a small short-lived pop on the news. Medivir’s main focus is in infectious diseases
No comments:
Post a Comment